Codexis, Inc. (CDXS)
Market Cap | 246.77M |
Revenue (ttm) | 70.14M |
Net Income (ttm) | -76.24M |
Shares Out | 70.30M |
EPS (ttm) | -1.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 435,172 |
Open | 3.540 |
Previous Close | 3.510 |
Day's Range | 3.450 - 3.719 |
52-Week Range | 1.450 - 4.910 |
Beta | 2.04 |
Analysts | Strong Buy |
Price Target | 7.50 (+114.9%) |
Earnings Date | May 2, 2024 |
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used f... [Read more]
Financial Performance
In 2023, Codexis's revenue was $70.14 million, a decrease of -49.39% compared to the previous year's $138.59 million. Losses were -$76.24 million, 127.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CDXS stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 114.90% from the latest price.
News
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway...
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive...
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care...
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™ manufacturing platform Board expertise encompasses oligo...
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth qua...
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
TnX transposase development collaboration leverages strengths of both companies TnX transposase development collaboration leverages strengths of both companies
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs Company to retain economic interest in biotherapeutic asset while remo...
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymes Deal creates strategic collaboration to enable more efficient R...
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13,...
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion Leader (KOL) event on Friday, December 8, 2023,...
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focuse...
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the 35th Annual Piper Sandler Health...
Codexis Reports Third Quarter 2023 Financial Results
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in four upcoming investor c...
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approac...
Codexis to Report Third Quarter 2023 Financial Results on November 2
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quar...
Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced President and Chief Executive Officer Stephen Dilly, MBBS, ...
Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Off...
Codexis to Participate in Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Confer...
Codexis Announces Agreement for Assignment and Assumption of San Carlos Facility Lease
Assignment results in estimated cumulative cash savings of more than $30M and supports projected cash runway to mid-2026 Assignment results in estimated cumulative cash savings of more than $30M and s...
Codexis Reports Second Quarter 2023 Financial Results
Company Recently Announced Enhanced Strategic Focus and Portfolio Prioritization Anticipate Demonstrating Gram-Scale Synthesis of ECO Synthesis™ Technology for RNAi Therapeutics Production by End of Y...
Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape
Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to four new employees as appro...